Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jon Strasser

Radiation Oncology Newark, DE Medical Doctor

NPI 1871537894 CMS profile 644405

4701 Ogletown Stanton Rd, Ste 1109, Newark, DE 19713

Open in the dashboard

General payments

$365,424

355 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jon Strasser of Newark, DE is reported in the CMS Open Payments database as having received $365,424 across 355 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Radiation Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $46,920 47
2024 General $47,745 57
2023 General $29,108 36
2022 General $54,054 55
2021 General $77,179 64
2020 General $33,399 29
2019 General $77,020 67

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jon Strasser
  • Radiation Oncology median
  • Middle half of Radiation Oncology
  • National median

In program year 2025, general payments to Jon Strasser were reported at $46,920. Among 3,409 Radiation Oncology profiles paid that year, the median was $172 and the middle half received between $61 and $514.

Show as a table
Year Jon Strasser Radiation Oncology median Middle half National median
2019 $77,020 $138 $48–$462 $163
2020 $33,399 $79 $26–$262 $114
2021 $77,179 $119 $37–$358 $132
2022 $54,054 $139 $43–$424 $149
2023 $29,108 $167 $57–$473 $160
2024 $47,745 $168 $56–$541 $164
2025 $46,920 $172 $61–$514 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $250,590 193 payments
  2. Regeneron Healthcare Solutions, Inc. $48,551 54 payments
  3. Genzyme Corporation $29,054 22 payments
  4. Elekta, Inc. $16,786 20 payments
  5. Medtronic USA, Inc. $9,807 11 payments
  6. E.R. Squibb & Sons, L.L.C. $4,335 4 payments
  7. Davol Inc. $2,000 1 payment
  8. AstraZeneca UK Limited $1,100 8 payments
  9. Siemens Medical Solutions USA, Inc. $905 6 payments
  10. Novocure Inc. $421 3 payments
  11. Other $1,875 33 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $247,377 82 payments
  2. Consulting Fee $81,964 25 payments
  3. Travel and Lodging $25,222 83 payments
  4. Food and Beverage $9,182 162 payments
  5. Honoraria $1,500 1 payment
  6. Education $179 2 payments
Products named General payments · program years 2019–2025
  1. IMFINZI Oncology $109,054 81 payments
  2. LIBTAYO $77,605 76 payments
  3. IMFINZI Cardiovascular And Metabolism $58,316 36 payments
  4. TAGRISSO $37,169 25 payments
  5. IMFINZI Oncology $33,021 37 payments
  6. MOSAIQ $14,812 15 payments
  7. MONACO $14,213 12 payments
  8. PROKNOW DS $14,213 12 payments
  9. OSTEOCOOL RF ABLATION $9,807 11 payments
  10. OPDIVO $4,222 3 payments
  11. Other $8,589 70 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$284,232

Medicare's payments for the services billed

Medicare patients

377

Average age 75

Services billed

3,323

227 women, 150 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 75%
Arthritis 44%
Diabetes 27%
Ischemic heart disease 27%
Chronic kidney disease 22%
Depression 20%
Atrial fibrillation 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LIBTAYO
  • Regeneron Healthcare Solutions, Inc. $18,257
$18,257 — —
TAGRISSO
  • AstraZeneca Pharmaceuticals LP $15,651
$15,651 — —
IMFINZI
  • AstraZeneca Pharmaceuticals LP $12,427
$12,427 — —
ENHERTU
  • Daiichi Sankyo Inc. $185
$185 — —
LYNPARZA
  • AstraZeneca Pharmaceuticals LP $69
$69 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

355 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record